Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the overall survival (OS) of oral linifanib
given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per
standard of care in subjects with advanced or metastatic HCC.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Angiogenesis Modulating Agents Molecular Mechanisms of Pharmacological Action Niacinamide Sorafenib